TG Therapeutics' multiple sclerosis drug Briumvi posted third-quarter sales growth of 51%, topping expectations and leading the biotechnology company to raise its full-year sales target. Earnings per share came in slightly below forecasts, while the stock recovered after an initial decline and hit a record high on November 10. Sales momentum, updated guidance and progress on a new formulation are central to gauging whether the smaller drugmaker can narrow the gap with Roche and Novartis.
Briumvi beats sales estimates, lifting the 2026 target
As of November 10, 2026, TG Therapeutics shares traded at $66.46 intraday, up nearly 5%. Global Briumvi sales reached $240 million in the third quarter, up 51% year over year and above the $233.9 million forecast tracked by FactSet. Earnings per share were 36 cents, a penny short of expectations, making the quarter a mixed result rather than a clean beat.
The company raised its full-year sales outlook to $1 billion from $950 million. It expects U.S. Briumvi sales of $915 million to $920 million; at the midpoint, that is $20 million higher than its previous U.S. estimate. CEO Michael Weiss said the higher revenue guidance reflected continued strength in the commercial business. TG Therapeutics also repurchased about $100 million of its shares during the quarter.
Shares rebound from around the 50-day average
After the results, TG Therapeutics shares briefly fell below their 50-day moving average before rebounding. The stock gained nearly 6% in the prior session, reclaiming its 21-day exponential moving average, and continued higher on November 10. It moved above $63.60, a technical reference level, and set a new high. The market data cited here were recorded at 11:08 a.m. ET that day and are not real-time.
The shares had earlier moved above a $58.92 consolidation-pattern entry point. TG Therapeutics had a Relative Strength Rating of 98 and a Composite Rating of 87 out of 99, and ranked ninth among 197 industry groups. Those measures reflect share-price performance and technical and fundamental screening criteria; they do not alter the fact that quarterly earnings per share fell slightly short of expectations.
Briumvi growth leads, but sales trail established rivals
Briumvi targets specific B cells and competes with Roche's Ocrevus and Novartis' Kesimpta. Launched in 2023, it has a smaller sales base than the two earlier-market products. In quarters with comparable year-over-year data, Briumvi sales growth has ranged from 51% to 149%. Growth has shown signs of slowing, but FactSet forecasts still point to double-digit sales growth through at least the end of next year.
Ocrevus generated $2.25 billion in third-quarter sales, up 6.4% year over year. Its growth was in the single digits in three of the past four quarters. Launched in 2017, it is a more mature product than Briumvi. Kesimpta, which launched in 2020, recorded third-quarter sales of $1.48 billion, up 21.4%. Its average growth over the past four quarters was 28.1%. Differences in launch timing and sales scale are important context when comparing the drugs' growth rates.
Subcutaneous Briumvi results expected around year-end
Briumvi is currently administered by intravenous infusion. After two initial doses, patients receive an infusion about every six months, with each session taking roughly an hour. TG Therapeutics is developing a subcutaneous formulation and expects to report Phase 3 results by year-end or in the first quarter of next year. The company has said it is targeting four doses per year.
Subcutaneous injections generally take less time and can be administered at home. Roche's Ocrevus Zunovo and Novartis' Kesimpta already use this route. TG Therapeutics also expects to launch a simplified intravenous formulation in mid-2027 and has identified 2028 as the potential launch window for the subcutaneous version. Weiss has also pointed to further data from the company's early-stage pipeline. The clinical results and development milestones will help determine the timeline for expanding Briumvi's commercial reach.